Outcomes of multiple salvage chemotherapy for advanced gastric cancer: Implications for clinical practice and trial design

Yong Wha Moon, SunYoung Rha, Hei Cheul Jeung, Chan Kim, Min Hee Hong, Hyun Chang, Jae Kyung Roh, Sung Hoon Noh, Byung Soo Kim, Hyuncheol Chung

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: We analyzed the natural history of advanced gastric cancer with sequential salvage chemotherapy following first-line treatment. Methods: We studied 532 patients with unresectable gastric adenocarcinoma who were treated at Yonsei Cancer Center (2000-2008). The patients were managed with multiple sequential salvage chemotherapy as allowed by performance status and toxicity profiles. The tumor response was assessed every two cycles. Results: Four hundred sixty patients received palliative chemotherapy and 72 received supportive care only. The median overall survival was 12.0 months for all patients, 12.1 months for the chemotherapy group, and 2.5 months for the supportive care group (P <0.001). In the chemotherapy group, 87% received first-line chemotherapy, 47% second-line, 23% third-line, 9% fourth-line, and 3% fifthline. Response rates were 24.8, 12.6, 10.9, 2.6, and 0% and disease control rates were 76.3, 60.1, 54.2, 54.2, and 53.3% for first-to fifth-line treatment, respectively. The median progression-free survival was 5.5, 3.4, 2.5, 1.9, and 2.0 months and overall survival was 12.1, 7.9, 5.5, 5.0, and 6.8 months. Performance status and metastatic pattern were consistent prognostic factors throughout salvage treatment. Conclusions: Clinical trials may be feasible in second-or third-line salvage chemotherapy for gastric cancer. Future clinical trials in these settings should take into account the low response rate, short progression-free survival, and the prognostic factors for optimal trial design.

Original languageEnglish
Pages (from-to)797-805
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume66
Issue number4
DOIs
Publication statusPublished - 2010 Sep 1

Fingerprint

Salvaging
Chemotherapy
Stomach Neoplasms
Clinical Trials
Drug Therapy
Disease-Free Survival
Disease control
Salvage Therapy
Survival
Natural History
Toxicity
Tumors
Neoplasms
Stomach
Adenocarcinoma
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Moon, Yong Wha ; Rha, SunYoung ; Jeung, Hei Cheul ; Kim, Chan ; Hong, Min Hee ; Chang, Hyun ; Roh, Jae Kyung ; Noh, Sung Hoon ; Kim, Byung Soo ; Chung, Hyuncheol. / Outcomes of multiple salvage chemotherapy for advanced gastric cancer : Implications for clinical practice and trial design. In: Cancer Chemotherapy and Pharmacology. 2010 ; Vol. 66, No. 4. pp. 797-805.
@article{e69286e22f274a52b442d5124a0666a0,
title = "Outcomes of multiple salvage chemotherapy for advanced gastric cancer: Implications for clinical practice and trial design",
abstract = "Purpose: We analyzed the natural history of advanced gastric cancer with sequential salvage chemotherapy following first-line treatment. Methods: We studied 532 patients with unresectable gastric adenocarcinoma who were treated at Yonsei Cancer Center (2000-2008). The patients were managed with multiple sequential salvage chemotherapy as allowed by performance status and toxicity profiles. The tumor response was assessed every two cycles. Results: Four hundred sixty patients received palliative chemotherapy and 72 received supportive care only. The median overall survival was 12.0 months for all patients, 12.1 months for the chemotherapy group, and 2.5 months for the supportive care group (P <0.001). In the chemotherapy group, 87{\%} received first-line chemotherapy, 47{\%} second-line, 23{\%} third-line, 9{\%} fourth-line, and 3{\%} fifthline. Response rates were 24.8, 12.6, 10.9, 2.6, and 0{\%} and disease control rates were 76.3, 60.1, 54.2, 54.2, and 53.3{\%} for first-to fifth-line treatment, respectively. The median progression-free survival was 5.5, 3.4, 2.5, 1.9, and 2.0 months and overall survival was 12.1, 7.9, 5.5, 5.0, and 6.8 months. Performance status and metastatic pattern were consistent prognostic factors throughout salvage treatment. Conclusions: Clinical trials may be feasible in second-or third-line salvage chemotherapy for gastric cancer. Future clinical trials in these settings should take into account the low response rate, short progression-free survival, and the prognostic factors for optimal trial design.",
author = "Moon, {Yong Wha} and SunYoung Rha and Jeung, {Hei Cheul} and Chan Kim and Hong, {Min Hee} and Hyun Chang and Roh, {Jae Kyung} and Noh, {Sung Hoon} and Kim, {Byung Soo} and Hyuncheol Chung",
year = "2010",
month = "9",
day = "1",
doi = "10.1007/s00280-010-1295-z",
language = "English",
volume = "66",
pages = "797--805",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

Outcomes of multiple salvage chemotherapy for advanced gastric cancer : Implications for clinical practice and trial design. / Moon, Yong Wha; Rha, SunYoung; Jeung, Hei Cheul; Kim, Chan; Hong, Min Hee; Chang, Hyun; Roh, Jae Kyung; Noh, Sung Hoon; Kim, Byung Soo; Chung, Hyuncheol.

In: Cancer Chemotherapy and Pharmacology, Vol. 66, No. 4, 01.09.2010, p. 797-805.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outcomes of multiple salvage chemotherapy for advanced gastric cancer

T2 - Implications for clinical practice and trial design

AU - Moon, Yong Wha

AU - Rha, SunYoung

AU - Jeung, Hei Cheul

AU - Kim, Chan

AU - Hong, Min Hee

AU - Chang, Hyun

AU - Roh, Jae Kyung

AU - Noh, Sung Hoon

AU - Kim, Byung Soo

AU - Chung, Hyuncheol

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Purpose: We analyzed the natural history of advanced gastric cancer with sequential salvage chemotherapy following first-line treatment. Methods: We studied 532 patients with unresectable gastric adenocarcinoma who were treated at Yonsei Cancer Center (2000-2008). The patients were managed with multiple sequential salvage chemotherapy as allowed by performance status and toxicity profiles. The tumor response was assessed every two cycles. Results: Four hundred sixty patients received palliative chemotherapy and 72 received supportive care only. The median overall survival was 12.0 months for all patients, 12.1 months for the chemotherapy group, and 2.5 months for the supportive care group (P <0.001). In the chemotherapy group, 87% received first-line chemotherapy, 47% second-line, 23% third-line, 9% fourth-line, and 3% fifthline. Response rates were 24.8, 12.6, 10.9, 2.6, and 0% and disease control rates were 76.3, 60.1, 54.2, 54.2, and 53.3% for first-to fifth-line treatment, respectively. The median progression-free survival was 5.5, 3.4, 2.5, 1.9, and 2.0 months and overall survival was 12.1, 7.9, 5.5, 5.0, and 6.8 months. Performance status and metastatic pattern were consistent prognostic factors throughout salvage treatment. Conclusions: Clinical trials may be feasible in second-or third-line salvage chemotherapy for gastric cancer. Future clinical trials in these settings should take into account the low response rate, short progression-free survival, and the prognostic factors for optimal trial design.

AB - Purpose: We analyzed the natural history of advanced gastric cancer with sequential salvage chemotherapy following first-line treatment. Methods: We studied 532 patients with unresectable gastric adenocarcinoma who were treated at Yonsei Cancer Center (2000-2008). The patients were managed with multiple sequential salvage chemotherapy as allowed by performance status and toxicity profiles. The tumor response was assessed every two cycles. Results: Four hundred sixty patients received palliative chemotherapy and 72 received supportive care only. The median overall survival was 12.0 months for all patients, 12.1 months for the chemotherapy group, and 2.5 months for the supportive care group (P <0.001). In the chemotherapy group, 87% received first-line chemotherapy, 47% second-line, 23% third-line, 9% fourth-line, and 3% fifthline. Response rates were 24.8, 12.6, 10.9, 2.6, and 0% and disease control rates were 76.3, 60.1, 54.2, 54.2, and 53.3% for first-to fifth-line treatment, respectively. The median progression-free survival was 5.5, 3.4, 2.5, 1.9, and 2.0 months and overall survival was 12.1, 7.9, 5.5, 5.0, and 6.8 months. Performance status and metastatic pattern were consistent prognostic factors throughout salvage treatment. Conclusions: Clinical trials may be feasible in second-or third-line salvage chemotherapy for gastric cancer. Future clinical trials in these settings should take into account the low response rate, short progression-free survival, and the prognostic factors for optimal trial design.

UR - http://www.scopus.com/inward/record.url?scp=77955865764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955865764&partnerID=8YFLogxK

U2 - 10.1007/s00280-010-1295-z

DO - 10.1007/s00280-010-1295-z

M3 - Article

C2 - 20221831

VL - 66

SP - 797

EP - 805

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -